bluuebunny/crossref_metadata_2025_split huggingface dataset:
Patterns and predictive factors of recurrences after complete resection for fibrolamellar hepatocellular carcinoma
Authors: El Maalouf G. , Le Tourneau C. , Paradis V. , Degos F. , Farges O. , Cortes A. , Raymond E. , Belghiti J. , Faivre S. 
Published: March 2020

15071 Background: Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare subtype of primary HCC which often arises in young patients without underlying hepatic disease or viral infection. Clinical and pathological factors of prognosis are warranted. Methods: Descriptive, univariate and multivariate analysis of survival parameters were analyzed in a monocenter cohort of FL-HCC patients completely resected. Main variables were WHO-PS, age, AJCC stage, AFP level and detailed pathological features including EGFR, p- AKT, and PTEN expression. Results: 23 consecutive patients (median age: 30, M/F:6/17) with pathologically reviewed FL-HCC were analyzed. Median tumor size was 11 cm (range 4–23) and 6 patients had AFP>200ng/ml. two patients had respectable metastasis (lung or peritoneum), 5 patients had vascular invasion and 3 patients had lymph node metastasis achieving the following AJCC staging: I (70%), III (22%) and IV (8%). With median follow-up of 36 months, 3-year survival was 76% . Median time of recurrence was 23 months. Sites of first recurrence were hepatic in 5 patients, extra-hepatic in 4 patients, and both in 3 of 12 patients who recurred (52%). Metastasis occurred in lung, peritoneum, bone, skin and lymph nodes. Expression of EGFR, p-AKT, and PTEN was found in 94%, 69% and 0% of patients, respectively. None of the clinical parameters including AJCC staging predicted survival. In multivariate analysis, bad prognostic factors of recurrence were satellite micro-nodules (p=0.04) and micro-vascular tumor invasion (p=0.03) on pathological specimens. There was a trend toward a better survival in patients with <30% EGFR expression (p=0.06). Conclusions: FL-HCC patients with primary complete resection may develop extra-hepatic metastasis (58%) or isolated intra-hepatic recurrence (42%) within a median follow-up of 2 years. Prognostic factors of survival are pathological satellite nodules and micro-vascular tumor invasion. No significant financial relationships to disclose.
The cell cycle regulation of anti-cancer bioactive peptide (ACBP) on gastric cancer cell lines
Authors: Su X. , Ouyang X. , Xu G. , Shen J. , Yan M. 
Published: March 2020

15087 Background: Anti-cancer bioactive peptide (ACBP) was extracted from the spleen of the goat suffered immune inducement by immunoreaction, supercentrifuge and ultra-filtration. Our previous studies have identified ACBP had significantly inhibited the growth of the human gastric cancer cell lines BGC-823 and MGC-803, the human rhinopharyngocele cell line CNE and the leukemic cell line. The in vivo experiments showed ACBP could dramatically repress the growth of tumor, and had few side-effects in the long-term toxic experiments. In clinical trials, ACBP could enhance the survival and life quality of the patients with advanced gastric cancer. In this study, we will explore the influence and mechanism of the effect of ACBP on cell cycle using human gastric cancer cell lines BGC-823 and MGC-803. Methods: Human gastric cancer cell lines BGC-823 and MGC-803 were cultured with different concentrations (10–25 ug/ml) of ACBP. The MTT method was employed to measure the growth inhibition rates of the cells with different concentrations of ACBP; the morphological changes were observed under the light microscope; the semi-quantitative RT-PCR was used to assay the changes of mRNA for p16,p21,p27,c-myc,cyclin D1,bax,bcl-2 gene. Results: Different concentrations of ACBP in the range of 10.0–25.0 μg/ml could inhibit the growth of BGC-823 and MGC-803 cell and such effect was both concentration and time dependent. 25.0 μg/ml ACBP had an inhibition rate (IR) of 84.4%, 72.3% and a median concentration (IC50) of 17.86 μg/ml, 13.16 ug/ml. After ACBP treatment, the cells showed typical apoptotic changes under the light microscope. On RT-PCR, the expressions of p16,p21,p27,bax mRNA in the two cell lines were markedly increased after ACBP treatment. On the contrary, the expression of c-myc,cyclin D1,bcl-2 mRNA in the two cell lines were obviously decreased after ACBP treatment. Conclusion: ACBP had markedly repressed the growth of BGC-823 and MGC-803 cell lines through inducing the cellular apoptosis. The possible mechanism is ACBP affects the cell cycle molecules expression including p16,p21,p27,cyclin D1 and regulate c-myc,bcl-2 and bax to induce apoptosis. No significant financial relationships to disclose.
Microarray analysis using paraffin embedded samples of gastric cancer (GC)
Authors: Uetake H. , Inokuchi M. , Sugihara K. , Danenberg K. , Danenberg P. V. 
Published: March 2020

15089 Background: In the 42nd annual meeting of ASCO, we reported our phase I/II study of S-1 plus CPT-11 study for metastatic GC. In the present study, microarray analysis using paraffin embedded samples of those patients were performed. Methods: Patients’ background; Histologically proven CRC with measurable metastatic lesions, PS 0–2, age< 80, adequate organ functions, and written informed consent. No prior chemotherapy except adjuvant setting was allowed. S-1 was administered orally, 80 mg/m2/day on 14 consecutive days with 14 days’ rest for 4 weeks, and CPT-11 was infused at the 80 mg/m2(RD)on days 1 and 8. Objective responses according to RECIST criteria were observed in 26 of the 42 pts (RR=62%). Median survival time was 444 days. Microarray analysis; Microarray analysis using paraffin embedded samples were performed (Responsegenetics Inc.). Results: In the scatter plotting, gene expression pattern of the stable disease (SD) group was similar to that of partial response (PR) group. Cluster analysis was successfully performed, that separated progressive disease (PD) group from SD/PR group (p<0.03). In pathway analysis, FGF signaling pathway and nicotinate and nicotinamide metabolism pathway was significantly important to predict the response to S-1 plus CPT-11 therapy. Conclusions: In S-1 plus biweekly CPT-11 therapy for metastatic GC, gene expression profile was supposed to be important for the prediction of the response and patient survival. No significant financial relationships to disclose.
CA 19–9 as a predictor of response and survival in patients with pancreatic cancer treated with gemcitabine and cisplatin based chemotherapy
Authors: Heilbrun L. K. , Khanna A. , Venkatramanamoorthy R. , Shields A. F. , Philip P. A. , Zalupski M. M. , El-Rayes B. F. 
Published: March 2020

15094 Background: Radiologic evaluation of the efficacy of chemotherapy (CT) regimens in pancreatic cancer is complicated by the retroperitoneal location and the desmoplastic nature of the tumor. The aim of this study was to evaluate the role of baseline CA 19–9 and the decrease in CA 19–9 after one cycle of CT as predictors of response, time to progression (TTP) , and overall survival (OS). Methods: We conducted 3 consecutive phase II trials evaluating gemcitabine and cisplatin based CT between 1997 and 2004. A retrospective chart review of the 111 patients yielded demographic data, best response status, TTP, OS, and CA19–9 levels. Response by CA 19–9 (R-CA19–9) was defined as a decrease of = 50% in CA 19–9 after the completion of the first cycle of chemotherapy. Results: The median age was 59 years with 60% males. Median performance status (PS) was 1. No significant difference was observed across the three trials with respect to age, sex, or PS. Baseline CA19–9 was known for 102 patients, and was dichotomized near the median as: < 1,000; and = 1,000 ng/mL. Lower baseline CA19–9 levels were not associated with higher radiologic response (RR) rate (p = 0.82): 22%, and 19%, respectively. Lower baseline CA19–9 was associated with longer OS, (p = 0.0057), as shown in a recent UK study. Median OS was 9.2, and 6.1 months, respectively. Similar results were observed for TTP, with p = 0.0146, and median TTP of 6.4 and 4.2 months, respectively. The change in CA19–9 from baseline to the end of treatment cycle 1 was available for 68 patients. The patients with R-CA19- 9 had a higher RR rate (29%) than did the other patients (24%), but not significantly so (p = 0.7495). The patients with R-CA19–9 had longer OS (median 8.7 vs 7.1 months) and longer TTP (median 7.1 vs 5.4 months), but not significantly so (p > 0.73 for each endpoint). Conclusions: Lower baseline CA19–9 (but not R-CA19–9 after treatment cycle 1) was positively associated with OS and TTP prognosis in our patient population. A 50% decrease in CA19–9 after the first cycle of chemotherapy was not a useful predictor of response, TTP, or OS. No significant financial relationships to disclose.
Mucinous cystadenocarcinoma (mca) of the appendix: Role of adjuvant therapy
Authors: Aggarwal C. , Gibbs J. , Wilding G. , Mashtare T. , Javle M. 
Published: March 2020

15131 Introduction: MCA is the most common (non-carcinoid) appendiceal cancer. Adjuvant 5-fluorouracil (5-FU) based systemic chemotherapy (ASC) is often considered for MCA cases after surgery, extrapolating data from colon cancer. Patients (pts) with peritoneal disease are considered for regional perfusional therapy. However, the role of adjuvant therapy in this setting has not yet been established. Methods: Retrospective analysis of cases with the diagnosis of MCA. Pts treated with curative intent and subsequent adjuvant therapy [ASC or Intraperitoneal Hyperthermic Chemotherapy (IPHC)] were included. Pts who received surgery alone were compared to those who received surgery in combination with adjuvant therapy. Estimation of the survival distribution of each group was performed using the Kaplan-Meier method. Statistical assessment of observed differences in the survival distributions was per the log-rank test. Analyses were also performed adjusting for age and sex using the stratified log rank test. A 0.05 nominal significance level was used in all testing. Results: A total of 34 consecutive pts were treated between 8/1973 and 4/2005 for MCA. Pt characteristics were: 15 males (44%), median age 50 yrs (range 27–79), 33 (97%) Caucasian, 30 (88%) had peritoneal metastasis at diagnosis. All patients underwent surgical resection; 26 (76%) underwent >1 of the following procedures. Surgeries were: right hemicolectomy (n=20, 58%), appendectomy (n=16, 47%), total abdominal hysterectomy (n=9, 26%), ileocolectomy (n=4, 11%) or debulking (n=12, 35%). Eight pts (23%) underwent IHPC with 5-FU (n=5), Mitomycin (n=2) or Yttrium90 (n=1). Thirteen patients (38%) underwent ASC: 5-FU based (n=12) or Paclitaxel/ Carboplatin (n=1). Pts who underwent surgery alone had a median survival of 40 months. Pts who had surgery and also received ASC or IPHC had a median survival of 53 months. There was no statistical difference in the overall survival between the groups after adjusting for age, sex and stage differences (p=0.1). Conclusions: MCA is an aggressive tumor; optimally treated with radical surgery even at an advanced stage. Larger studies are required to determine the value of ASC or IPHC in this setting. No significant financial relationships to disclose.
Adjuvant chemotherapy of cisplatin, 5-fluorouracil (5-FU) plus leucovorin (LV) for esophageal cancer: A case-matched cohort study in east china
Authors: Zhang J. , Xiang J. , Zhang Y. , Zhou X. 
Published: March 2020

15135 Background: There are very few prospective randomized clinical trials regarding the adjuvant chemotherapy of esophageal cancer. This study is to compare the survival between the patients who received adjuvant chemotherapy of cisplatin, 5-Fluorouracil (5-FU) plus leucovorin (LV) and those who did not. Methods: Between 1998 and 2004, 90 esophageal cancer patients with adjuvant chemotherapy, and clinic-pathologically well- matched 180 patients without chemotherapy, were included in this study. Results: There was no significant difference for disease-free-survival and overall-survival in stage I (P=0.59&p=0.59), stage II (P=0.2778&P=0.2778) and stage III patients (P=0.695 &P=0.8667) between observation group and chemotherapy group. Chemotherapy was most effective for the patients who had metastasis in cervical and /or celiac lymph node (IVa subgroup) by both univariate analysis and multivariate COX regression model. 1 and 3-year DFS and OS are significantly better than those who did not receive the chemotherapy(P= 0.038,and 0.01, respectively). Among the factors evaluated by immunohistochemical staining, Bcl-2 expression in the primary tumor was a worse prognostic factor, and was more predictive in adjuvant chemotherapy group than no chemotherapy group. Conclusions: Adjuvant chemotherapy significantly improved the treatment result of stage IVa patients. Bcl-2 could be potentially used to analyze the prognosis and guild the adjuvant treatment in esophageal cancer. No significant financial relationships to disclose.
A method to identify the best candidates for multiorgan resection among patients with T4 gastric carcinoma
Authors: Onate-Ocana L. F. , Aiello-Crocifoglio V. , Gallardo-Rincón D. , Brom-Valladares R. , Becker M. , Herrera-Goepfert R. , Carrillo J. F. , Beltrán-Ortega A. 
Published: March 2020

15141 Background: Background: Indications for gastrectomy in T4 gastric carcinoma (GC) remain controversial. Our aim was to develop a method for the selection of patients with T4 GC with best chances to receive a benefit from multiorgan resection. Methods: We analyzed a cohort of patients with T4 GC treated from January 1987 to December 2005. Relevant clinical, pathological and therapeutic variables were recorded. Prognostic factors associated with survival were defined by Kaplan-Meier and Cox’s methods. Factors associated to surgical morbidity were selected by Logistic Regression analysis. Results: 718 patients were included (gastrectomy performed in 169). Presence of metastasis (Hazard ratio=1.68 [HR], 95% confidence interval [CI] 1.19–2.36), albumin <3 g/dL plus lymphocytes <1,000 cells/mm3 (HR=2.9, 95% CI 1.8–4.6), presence of ascites (HR=2.1, 95% CI 1.06–4.2), 50 years old or more (HR=1.37, 95% CI 1.02–1.8) and surgical resection not possible (HR=2.6, 95% CI 1.7–4.1) define patients with the worst survival (model p=0.00001). Including only patients who underwent surgical resection, presence of metastases, extent of gastrectomy, serum albumin level and R1-R2 residual were determinants of poor survival (model p=0.00001). Surgical morbidity and mortality were 39% and 10.7%, respectively. The significant factor associated to surgical morbidity were extent of gastrectomy, age, serum albumin and lymphocyte count (model p=0.0001). Conclusion: The decision to perform a curative gastrectomy in patients with T4 GC must be balanced between the chances of long-term survival and the chances to survive a potentially fatal operation. Abscence of lymph node and distant metastases, adequate blood lymphocyte count and normal serum albumin levels could help to select those patients with high probability to receive benefit from multiorgan resection as long as R0 resection is performed. The role of preoperative chemoradiation or perioperative chemotherapy in T4 GC must be defined. No significant financial relationships to disclose.
A single center review of the experience with mitomycin C (MMC) and the risk of thrombotic thrombocytopenic purpura (TTP)/hemolytic uremic syndrome (HUS)
Authors: Arce-Lara C. E. , Cataland S. , Brady C. , Kraut E. , Otterson G. , Villalona-Calero M. , Bekaii-Saab T. 
Published: March 2020

15167 Background: MMC related TTP/HUS has been reported between 4 and 15%, with a higher incidence in patients receiving cumulative doses of 60 mg or higher. It tends to occur within 4 months of drug administration independently of patients’ cancer status. The ability of MMC to upregulate enzymes relevant for new cytototoxic agents (topoisomerase I for CPT-11 and thymidine phosphorylase for capecitabine) make phamacobiologically based therapeutic combinations including MMC attractive. Methods: All patients (n=100) that participated in four institutional clinical studies from 2000 through 2004 were included. The studies were OSU 9947 (phase I trial of CPT-11 and MMC in solid tumors, n=31) OSU 0151 (phase II trial of CPT-11 and MMC in advanced esophageal and stomach cancer, n=41) OSU 0155 (phase II trial of CPT-11 and MMC in patients with refractory breast cancer, n=26) OSU 0330 (phase I study of capecitabine and MMC in patients with advanced GI tumors n=2). In each study, the maximum cumulative dose of MMC was 36 mg/m2. All patients were followed for clinical signs or symptoms of TTP/HUS including the presence of anemia, thrombocytopenia and renal insufficiency and had a thorough review of the peripheral smear. Results: The median cumulative dose was 12 mg/m2 (range 3–36 mg/m2). No patients met the clinical diagnosis of TTP/HUS except for one patient had anemia, thrombocytopenia and renal insufficiency but did not manifest any other findings consistent with TTP/HUS such as changes in mental status, azotemia or any other clinical symptom. The laboratory abnormalities resolved without intervention within seven days with subsequent continuation on the clinical trial. Conclusions: In this study we have demonstrated that by capping the cumulative dose of MMC to 36 mg/m2, the incidence of TTP/HUS is minimal. Furthermore, our preliminary analysis of an additional 100 patients treated with MMC at OSU shows no reported cases of TTP/HUS (additional data will be presented at the meeting). Since MMC is effective in a wide variety of solid tumors including breast, lung and GI malignancies and is inexpensive and easy to administer, further exploration of MMC in the treatment of solid malignancies is indicated including rational combination studies. No significant financial relationships to disclose.
Interim results of a weekly, metronomic dosing of paclitaxel, oxaliplatin, leucovorin, 5-FU (POLF) in the treatment of metastatic pancreatic cancer (PC)
Authors: Chue B. 
Published: March 2020

15175 Background: Metastatic PC has a dismal prognosis and few effective therapies, resulting in early death and poor quality of life. Weekly “metronomic dosing” of chemotherapy allows for increase dose density, dose intensity, and anti-angiogenic effects, yet affords good tolerability, allowing for a better quality of life and perhaps better efficacy. We report the encouraging interim results of the first nine patients treated twelve weeks with this POLF regimen. Methods: Nine patients ages 35 to 75 with metastatic biopsy proven PC were treated with weekly POLF (P: 60 mg/m2, O: 50mg/ m2, L: 20 mg/m2, F: 425 mg/m2) for twelve weeks. One patient (A.B.) also received intermittent Cetuximab. Glutathione, calcium, and magnesium were used to prevent Oxaliplatin- related neuropathy. Patients were seen weekly. Sequential CA 19–9 levels and CT scans were obtained. Results: After 12 weeks of treatments, 7/9 patients had greater than 50% reduction of CA 19–9 levels (see table ), improvement of cancer-related symptoms and shrinkage of tumor. Patient D.P. had a bilirubin of 27 and patient L.C. had bilirubin of 9.6, both of which normalized with treatment without need for stent placement. Patient A.B. was severely debilitated (ECOG 4) following progression of disease after 2 prior lines of chemotherapy but is alive and well after two years since diagnosis, with ECOG 0. The regimen was well tolerated with only one grade 3 neurotoxicity (L.C.) and one grade 3 diarrhea (B.P.). Median survival has not been reached. Conclusions: Weekly combination of Paclitaxel, Oxaliplatin, Leucovorin, and 5-FU has significant activity against advanced PC with manageable side effects. A Phase II study is opened to enrollment, and we welcome participation. [Table: see text] No significant financial relationships to disclose.
Factors affecting survival in pancreatic carcinoma: Analysis from a oncology unit of a general hospital in Peru
Authors: Pimentel P. , Beltran B. E. , Riva L. , Reategui R. , Portugal K. , Del Castillo R. 
Published: March 2020

15184 Background: Pancreatic carcinoma (PC) is one of the most devasting neoplasm , usually diagnosed in advanced stage with a poor outcome . We present the experience in a Medical Oncology Unit in a National General Hospital, analysing the risk factors for survival in PC. Methods: This is a retrospective study with data collected on 224 patients with PC in all stages between 1999 and 2004. Only 82 patients were included because the rest had clinical and radiological diagnosis without histological studies. Survival was calculated using the Kaplan-Meier method. Clinical, surgical and histopathological records were examined by univariate and multivariate analysis to identify the independent prognostic predictors of survival. Results: All of patients had a confirmed hystopathologic diagnosis of PC. Median age was 69 years ( 33–87), 38/82 (46%) were women; 65/82 (79%) had tumor localized in pancreas head and 22/82 (26%) were stage I /II . 60/80 ( 73%) had advanced stages III/IV. Only 19/82 ( 23%) had Whipple surgery with curative intent. On diagnosis Performance status(PS). 2- 4 was present in 56% (46) .For different reasons only 16/82 received treatment based in gemcitabine. Median overall survival for all patients was 5.4 months, with 1 year survival of 32% .On univariate analysis, P.S. ( p=0.077), Whipple surgery with curative intent (p=0.026), Gemcitabine treatment (p=0.002) and CEA ( p=0.002) significantly influence survival. On multivariate analysis, only P.S (p< 0.05), Gemcitabine based treatment ( p=0.005) and CEA ( p= 0.045) independently influence survival. Conclusions: In this retrospective analysis we identified performance status, CEA and Gemcitabine based treatments as independent prognostic factors that influence survival in PC, adressing the role of standar gemcitabine regimens in the treatment of advanced PC and the need of continue research for improve the outcome of this challenging disease. No significant financial relationships to disclose.